Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02488967 · ClinicalTrials.gov registry record · Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
A Phase 3 study of Stage IIIA Breast Cancer and HER2/Neu Negative, sponsored by NRG Oncology.
- Active
- Registry status
- Phase 3
- Development phase
- 782
- Enrollment target
- 20
- Study locations
NCT02488967 is a Phase 3 study of Stage IIIA Breast Cancer and HER2/Neu Negative that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 782 participants, above the 254-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (208% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT02488967, a Phase 3 study of Stage IIIA Breast Cancer and HER2/Neu Negative, is active but no longer recruiting, sponsored by NRG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 782 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- DRUG Doxorubicin Hydrochloride
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Regional Hospital - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Arizona Breast Cancer Specialists-Gilbert - Gilbert
- Virginia G Piper Cancer Care-Glendale - Glendale
- CTCA at Western Regional Medical Center - Goodyear
- Arizona Center for Cancer Care-Peoria - Peoria
- Arizona Oncology Associates-Biltmore Cancer Center - Phoenix
- Arizona Breast Cancer Specialists-Phoenix - Phoenix
- Arizona Oncology-Deer Valley Center - Phoenix
Alabama
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2015-07-26 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02488967
The ClinicalTrials.gov registry entry for NCT02488967 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 782 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (208% higher). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02488967 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Alaska, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02488967 about?
NCT02488967 is a clinical study titled "Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer". This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel...
What is the current status of trial NCT02488967?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 782 participants. The study started on 2015-07-26. Estimated completion is 2026-10-31.
What conditions does trial NCT02488967 study?
This clinical trial studies the following conditions: Stage IIIA Breast Cancer, HER2/Neu Negative, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma, Breast Adenocarcinoma.
What interventions are being tested in trial NCT02488967?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Doxorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02488967?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02488967 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 3
-
Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery
COMPLETED · Phase 3
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.